Literature DB >> 27607362

Bone mineral density is reduced by telmisartan in male spontaneously hypertensive rats.

Antonio Marcos Birocale1, Ana Raquel Santos Medeiros2, Leandro Dias Gonçalves Ruffoni3, Liliam Takayama4, José Martins de Oliveira5, Keico Okino Nonaka3, Rosa Maria Rodrigues Pereira4, Nazaré Souza Bissoli6.   

Abstract

BACKGROUND: Telmisartan, an angiotensin AT1 receptor blocker, and treadmill running were compared for their effects on bone mineral density (BMD) and biomechanical properties of male spontaneously hypertensive rats (SHR). It was hypothesized that running (18m/min/60min/d) and telmisartan (5mg/kg/d) would have a positive effect on bone parameters.
METHODS: Three-month-old male SHRs were divided into three groups: sedentary (S), telmisartan (T), and exercise (E). At the end of an 8-week protocol, femur and lumbar vertebrae were analyzed by dual-energy X-ray absorptiometry (DXA) for bone mineral density and by the three-point bending test for biomechanical properties. Blood pressure in all groups was measured by a tail-cuff manometer.
RESULTS: Telmisartan and treadmill running reduced blood pressure when compared to the sedentary group; however, telmisartan did not improve bone characteristics. Instead, it reduced BMD of femur total and lumbar vertebrae and worsened bone biomechanic properties. Treadmill running maintained bone characteristics and hence was effective in maintaining bone health.
CONCLUSION: Results showed that telmisartan negatively affected bones suggesting that caution should be taken in possible therapeutic applications for protecting bone health in hypertensive conditions. More studies are necessary to clarify the mechanisms through which telmisartan favors bone loss in this model.
Copyright © 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Bone loss; Exercise; Hypertension; Telmisartan

Mesh:

Substances:

Year:  2016        PMID: 27607362     DOI: 10.1016/j.pharep.2016.06.014

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  3 in total

1.  Initiation of antihypertensive monotherapy and incident fractures among Medicare beneficiaries.

Authors:  Jennifer L Hargrove; Yvonne M Golightly; Virginia Pate; Carri H Casteel; Laura R Loehr; Stephen W Marshall; Til Stürmer
Journal:  Inj Epidemiol       Date:  2017-10-18

2.  Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.

Authors:  Victor Gustavo Balera Brito; Mariana Sousa Patrocinio; Maria Carolina Linjardi de Sousa; Ayná Emanuelli Alves Barreto; Sabrina Cruz Tfaile Frasnelli; Vanessa Soares Lara; Carlos Ferreira Santos; Sandra Helena Penha Oliveira
Journal:  Front Pharmacol       Date:  2020-11-11       Impact factor: 5.810

3.  Effects of high-intensity interval training in more or less active mice on biomechanical, biophysical and biochemical bone parameters.

Authors:  Emanuel E C Polisel; Wladimir R Beck; Pedro P M Scariot; Taciane M M Pejon; Claudio A Gobatto; Fúlvia B Manchado-Gobatto
Journal:  Sci Rep       Date:  2021-03-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.